In the setting of cardiorenal syndrome(s) (CRS), the main pathophysiological triggers of renal disease progression include increases in renal venous pressure, maladaptive activation of the renin-angiotensin-aldosterone (RAAS) and the sympathetic nervous systems, and a chronic inflammatory state. In acute decompensated heart failure (HF)/type 1 CRS, diuretics remain the mainstay of first-line therapy in order to prevent congestion and renal venous hypertension. In chronic HF/type 2 CRS, RAAS multiple inhibition has been recommended in addition to diuretics. However, cotreatment with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers and mineralocorticoid receptor antagonists is likely to lead to more frequent occurrences of hyperkalemia and worsening renal function. In this review, the main pharmacological therapies of acute and chronic CRS are discussed regarding their indication as well as intended and side effects. Future therapies are suggested, underlining that a multidisciplinary approach to a deeper understanding of the pathophysiology of CRS is still required to improve specific treatment and clinical outcome.

Keywords:
Cardiorenal syndromes, Acute and chronic heart failure, Therapeutics, Anemia
1.
Elsayed EF, Tighiouart H, Griffith J, Kurth T, Levey AS, Salem D, Sarnak MJ, Weiner DE: Cardiovascular disease and subsequent kidney disease. Arch Intern Med 2007;167:1130-1136.
[PubMed]
https://doi.org/10.1001/archinte.167.11.1130
2.
Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539.
[PubMed]
https://doi.org/10.1016/j.jacc.2008.07.051
3.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, Jessup M, Konstam MA, Mancini DM, Michl K, Oates JA, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update incorporated into the ACC/AHA 2005 Guidelines for the Diagnosis and Management of Heart Failure in Adults: a Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the International Society for Heart and Lung Transplantation. J Am Coll Cardiol 2009;53:e1-e90.
[PubMed]
https://doi.org/10.1016/j.jacc.2008.11.013
4.
House AA, Anand I, Bellomo R, et al: Definition and classification of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010;25:1416-1420.
[PubMed]
https://doi.org/10.1093/ndt/gfq136
5.
Dickstein K, Cohen-Solal A, Filippatos G, McMurray JJ, Ponikowski P, Poole-Wilson PA, Stromberg A, van Veldhuisen DJ, Atar D, Hoes AW, Keren A, Mebazaa A, Nieminen M, Priori SG, Swedberg K: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-989.
[PubMed]
https://doi.org/10.1016/j.ejheart.2008.08.005
6.
Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
[PubMed]
https://doi.org/10.1186/cc5713
7.
Tanaka M, Yoshida H, Furuhashi M, Togashi N, Koyama M, Yamamoto S, Yamashita T, Okazaki Y, Ishimura S, Ota H, Hasegawa T, Miura T: Deterioration of renal function by chronic heart failure is associated with congestion and oxidative stress in the tubulointerstitium. Intern Med 2011;50:2877-2887.
[PubMed]
https://doi.org/10.2169/internalmedicine.50.5925
8.
Heywood JT, Fonarow GC, Costanzo MR, Mathur VS, Wigneswaran JR, Wynne J: High prevalence of renal dysfunction and its impact on outcome in 118,465 patients hospitalized with acute decompensated heart failure: a report from the ADHERE database. J Card Fail 2007;13:422-430.
[PubMed]
https://doi.org/10.1016/j.cardfail.2007.03.011
9.
Smith GL, Lichtman JH, Bracken MB, Shlipak MG, Phillips CO, DiCapua P, Krumholz HM: Renal impairment and outcomes in heart failure: systematic review and meta-analysis. J Am Coll Cardiol 2006;47:1987-1996.
[PubMed]
https://doi.org/10.1016/j.jacc.2005.11.084
10.
Klein L, Massie BM, Leimberger JD, O'Connor CM, Pina IL, Adams KF Jr, Califf RM, Gheorghiade M: Admission or changes in renal function during hospitalization for worsening heart failure predict postdischarge survival: results from the Outcomes of a Prospective Trial of Intravenous Milrinone for Exacerbations of Chronic Heart Failure (OPTIME-CHF). Circ Heart Fail 2008;1:25-33.
[PubMed]
https://doi.org/10.1161/CIRCHEARTFAILURE.107.746933
11.
Cowie MR, Komajda M, Murray-Thomas T, Underwood J, Ticho B: Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the Prospective Outcomes Study in Heart Failure (POSH). Eur Heart J 2006;27:1216-1222.
[PubMed]
https://doi.org/10.1093/eurheartj/ehi859
12.
McMurray JJ, Adamopoulos S, Anker SD, et al: ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2012;14:803-869.
[PubMed]
https://doi.org/10.1093/eurjhf/hfs105
13.
Damman K, Navis G, Smilde TD, Voors AA, van der Bij W, van Veldhuisen DJ, Hillege HL: Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-878.
[PubMed]
https://doi.org/10.1016/j.ejheart.2007.05.010
14.
Novello FC, Sprague JM: Benzothiadiazines as novel diuretics. J Am Chem Soc 1957;79:2028-2029.
https://doi.org/10.1021/ja01565a079
15.
Robson AO, Kerr DN, Ashcroft R, Teasdale G: The diuretic response to frusemide. Lancet 1964;2:1085-1088.
[PubMed]
https://doi.org/10.1016/S0140-6736(64)92608-X
16.
Jessup M, Abraham WT, Casey DE, Feldman AM, Francis GS, Ganiats TG, Konstam MA, Mancini DM, Rahko PS, Silver MA, Stevenson LW, Yancy CW: 2009 focused update: ACCF/AHA Guidelines for the Diagnosis and Management of Heart Failure in Adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation 2009;119:1977-2016.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.109.192064
17.
Krishna GG, Shulman MD, Narins RG: Clinical use of the potassium-sparing diuretics. Semin Nephrol 1988;8:354-364.
[PubMed]
18.
Maxwell AP, Ong HY, Nicholls DP: Influence of progressive renal dysfunction in chronic heart failure. Eur J Heart Fail 2002;4:125-130.
[PubMed]
https://doi.org/10.1016/S1388-9842(01)00238-0
19.
Johnston GD, Nicholls DP, Leahey WJ: The dose-response characteristics of the acute non-diuretic peripheral vascular effects of frusemide in normal subjects. Br J Clin Pharmacol 1984;18:75-81.
[PubMed]
https://doi.org/10.1111/j.1365-2125.1984.tb05024.x
20.
Haerer W, Bauer U, Sultan N, Cernoch K, Mouselimis N, Fehske KJ, Hetzel M, Stauch M, Hombach V: Acute and chronic effects of a diuretic monotherapy with piretanide in congestive heart failure - a placebo-controlled trial. Cardiovasc Drugs Ther 1990;4:515-521.
[PubMed]
https://doi.org/10.1007/BF01857763
21.
Patterson JH, Adams KF Jr, Applefeld MM, Corder CN, Masse BR: Oral torsemide in patients with chronic congestive heart failure: effects on body weight, edema, and electrolyte excretion. Torsemide Investigators Group. Pharmacotherapy 1994;14:514-521.
[PubMed]
22.
Faris R, Flather M, Purcell H, Henein M, Poole-Wilson P, Coats A: Current evidence supporting the role of diuretics in heart failure: a meta analysis of randomised controlled trials. Int J Cardiol 2002;82:149-158.
[PubMed]
https://doi.org/10.1016/S0167-5273(01)00600-3
23.
Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, Stevenson LW, Francis GS, Leier CV, Miller LW: Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA 2005;294:1625-1633.
[PubMed]
https://doi.org/10.1001/jama.294.13.1625
24.
Hasselblad V, Gattis Stough W, Shah MR, Lokhnygina Y, O'Connor CM, Califf RM, Adams KF Jr: Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-1069.
[PubMed]
https://doi.org/10.1016/j.ejheart.2007.07.011
25.
Neuberg GW, Miller AB, O'Connor CM, Belkin RN, Carson PE, Cropp AB, Frid DJ, Nye RG, Pressler ML, Wertheimer JH, Packer M: Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-38.
[PubMed]
https://doi.org/10.1067/mhj.2002.123144
26.
Felker GM, Lee KL, Bull DA, et al: Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364:797-805.
[PubMed]
https://doi.org/10.1056/NEJMoa1005419
27.
Testani JM, Chen J, McCauley BD, Kimmel SE, Shannon RP: Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-272.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.109.933275
28.
Yilmaz MB, Gayat E, Salem R, Lassus J, Nikolaou M, Laribi S, Parissis J, Follath F, Peacock WF, Mebazaa A: Impact of diuretic dosing on mortality in acute heart failure using a propensity-matched analysis. Eur J Heart Fail 2011;13:1244-1252.
[PubMed]
https://doi.org/10.1093/eurjhf/hfr121
29.
Allen LA, Turer AT, Dewald T, Stough WG, Cotter G, O'Connor CM: Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol 2010;105:1794-1797.
[PubMed]
https://doi.org/10.1016/j.amjcard.2010.01.355
30.
Ravnan SL, Ravnan MC, Deedwania PC: Pharmacotherapy in congestive heart failure: diuretic resistance and strategies to overcome resistance in patients with congestive heart failure. Congest Heart Fail 2002;8:80-85.
[PubMed]
https://doi.org/10.1111/j.1527-5299.2002.0758.x
31.
Dormans TP, van Meyel JJ, Gerlag PG, Tan Y, Russel FG, Smits P: Diuretic efficacy of high dose furosemide in severe heart failure: bolus injection versus continuous infusion. J Am Coll Cardiol 1996;28:376-382.
[PubMed]
https://doi.org/10.1016/0735-1097(96)00161-1
32.
Channer KS, McLean KA, Lawson-Matthew P, Richardson M: Combination diuretic treatment in severe heart failure: a randomised controlled trial. Br Heart J 1994;71:146-150.
[PubMed]
https://doi.org/10.1136/hrt.71.2.146
33.
Bock JS, Gottlieb SS: Cardiorenal syndrome: new perspectives. Circulation 2010;121:2592-2600.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.109.886473
34.
Elkayam U, Ng TM, Hatamizadeh P, Janmohamed M, Mehra A: Renal vasodilatory action of dopamine in patients with heart failure: magnitude of effect and site of action. Circulation 2008;117:200-205.
[PubMed]
https://doi.org/10.1161/CIRCULATIONAHA.107.737106
35.
Giamouzis G, Butler J, Starling RC, Karayannis G, Nastas J, Parisis C, Rovithis D, Economou D, Savvatis K, Kirlidis T, Tsaknakis T, Skoularigis J, Westermann D, Tschope C, Triposkiadis F: Impact of dopamine infusion on renal function in hospitalized heart failure patients: results of the Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial. J Card Fail 2010;16:922-930.
[PubMed]
https://doi.org/10.1016/j.cardfail.2010.07.246
36.
Chen HH, Anstrom KJ, Givertz MM, et al: Low-dose dopamine or low-dose nesiritide in acute heart failure with renal dysfunction: the ROSE acute heart failure randomized trial. JAMA 2013;310:2533-2543.
[PubMed]
37.
Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. JAMA 2007;297:1332-1343.
[PubMed]
https://doi.org/10.1001/jama.297.12.1332
38.
Massie BM, O'Connor CM, Metra M, Ponikowski P, Teerlink JR, Cotter G, Weatherley BD, Cleland JG, Givertz MM, Voors A, DeLucca P, Mansoor GA, Salerno CM, Bloomfield DM, Dittrich HC: Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-1428.
[PubMed]
https://doi.org/10.1056/NEJMoa0912613
39.
Paterna S, Di Pasquale P, Parrinello G, Fornaciari E, Di Gaudio F, Fasullo S, Giammanco M, Sarullo FM, Licata G: Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 2005;45:1997-2003.
[PubMed]
https://doi.org/10.1016/j.jacc.2005.01.059
40.
Costanzo MR, Guglin ME, Saltzberg MT, Jessup ML, Bart BA, Teerlink JR, Jaski BE, Fang JC, Feller ED, Haas GJ, Anderson AS, Schollmeyer MP, Sobotka PA: Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-683.
[PubMed]
https://doi.org/10.1016/j.jacc.2006.07.073
41.
Bart BA, Goldsmith SR, Lee KL, et al: Ultrafiltration in decompensated heart failure with cardiorenal syndrome. N Engl J Med 2012;367:2296-2304.
[PubMed]
https://doi.org/10.1056/NEJMoa1210357
42.
Ferreira A, Bettencourt P, Dias P, Pestana M, Serrao P, Soares-da-Silva P, Cerqueira-Gomes M: Neurohormonal activation, the renal dopaminergic system and sodium handling in patients with severe heart failure under vasodilator therapy. Clin Sci (Lond) 2001;100:557-566.
[PubMed]
https://doi.org/10.1042/CS20000321
43.
den Uil CA, Lagrand WK, Valk SD, Spronk PE, Simoons ML: Management of cardiogenic shock: focus on tissue perfusion. Curr Probl Cardiol 2009;34:330-349.
[PubMed]
https://doi.org/10.1016/j.cpcardiol.2009.04.002
44.
Mullens W, Abrahams Z, Francis GS, Skouri HN, Starling RC, Young JB, Taylor DO, Tang WH: Sodium nitroprusside for advanced low-output heart failure. J Am Coll Cardiol 2008;52:200-207.
[PubMed]
https://doi.org/10.1016/j.jacc.2008.02.083
45.
Schulz V, Bonn R, Kindler J: Kinetics of elimination of thiocyanate in 7 healthy subjects and in 8 subjects with renal failure. Klin Wochenschr 1979;57:243-247.
[PubMed]
https://doi.org/10.1007/BF01477493
46.
Reichert S, Ignaszewski A: Molecular and physiological effects of nesiritide. Can J Cardiol 2008;24(Suppl B):15B-18B.
[PubMed]
https://doi.org/10.1016/S0828-282X(08)71024-9
47.
Sackner-Bernstein JD, Kowalski M, Fox M, Aaronson K: Short-term risk of death after treatment with nesiritide for decompensated heart failure: a pooled analysis of randomized controlled trials. JAMA 2005;293:1900-1905.
[PubMed]
https://doi.org/10.1001/jama.293.15.1900
48.
O'Connor CM, Starling RC, Hernandez AF, et al: Effect of nesiritide in patients with acute decompensated heart failure. N Engl J Med 2011;365:32-43.
[PubMed]
https://doi.org/10.1056/NEJMoa1100171
49.
Gottlieb SS, Stebbins A, Voors AA, Hasselblad V, Ezekowitz JA, Califf RM, O'Connor CM, Starling RC, Hernandez AF: Effects of nesiritide and predictors of urine output in acute decompensated heart failure: results from ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide and Decompensated Heart Failure). J Am Coll Cardiol 2013;62:1177-1183.
[PubMed]
https://doi.org/10.1016/j.jacc.2013.04.073
50.
Jard S: Mechanisms of action of vasopressin and vasopressin antagonists. Kidney Int Suppl 1988;26:S38-S42.
[PubMed]
51.
Nakamura Y, Haneda T, Osaki J, Miyata S, Kikuchi K: Hypertrophic growth of cultured neonatal rat heart cells mediated by vasopressin V(1A) receptor. Eur J Pharmacol 2000;391:39-48.
[PubMed]
https://doi.org/10.1016/S0014-2999(99)00775-X
52.
Kalra PR, Anker SD, Coats AJ: Water and sodium regulation in chronic heart failure: the role of natriuretic peptides and vasopressin. Cardiovasc Res 2001;51:495-509.
[PubMed]
https://doi.org/10.1016/S0008-6363(01)00297-8
53.
Aditya S, Rattan A: Vaptans: a new option in the management of hyponatremia. Int J Appl Basic Med Res 2012;2:77-83.
[PubMed]
https://doi.org/10.4103/2229-516X.106347
54.
Decaux G, Soupart A, Vassart G: Non-peptide arginine-vasopressin antagonists: the vaptans. Lancet 2008;371:1624-1632.
[PubMed]
https://doi.org/10.1016/S0140-6736(08)60695-9
55.
Robertson GL: Vaptans for the treatment of hyponatremia. Nat Rev Endocrinol 2011;7:151-161.
[PubMed]
https://doi.org/10.1038/nrendo.2010.229
56.
Udelson JE, Orlandi C, O'Brien T, Sequeira R, Ouyang J, Konstam MA: Vasopressin receptor blockade in patients with congestive heart failure: results from a placebo-controlled, randomized study comparing the effects of tolvaptan, furosemide, and their combination (abstract). J Am Coll Cardiol 2002;39:156.
https://doi.org/10.1016/S0735-1097(02)80688-X
57.
Schrier RW, Gross P, Gheorghiade M, Berl T, Verbalis JG, Czerwiec FS, Orlandi C: Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006;355:2099-2112.
[PubMed]
https://doi.org/10.1056/NEJMoa065181
58.
Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW: Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients. J Am Coll Cardiol 2006;47:1615-1621.
[PubMed]
https://doi.org/10.1016/j.jacc.2005.11.071
59.
Udelson JE, Orlandi C, Ouyang J, Krasa H, Zimmer CA, Frivold G, Haught WH, Meymandi S, Macarie C, Raef D, Wedge P, Konstam MA, Gheorghiade M: Acute hemodynamic effects of tolvaptan, a vasopressin V2 receptor blocker, in patients with symptomatic heart failure and systolic dysfunction: an international, multicenter, randomized, placebo-controlled trial. J Am Coll Cardiol 2008;52:1540-1545.
[PubMed]
https://doi.org/10.1016/j.jacc.2008.08.013
60.
Gheorghiade M, Gattis WA, O'Connor CM, Adams KF Jr, Elkayam U, Barbagelata A, Ghali JK, Benza RL, McGrew FA, Klapholz M, Ouyang J, Orlandi C: Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-1971.
[PubMed]
https://doi.org/10.1001/jama.291.16.1963
61.
Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C: Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297:1319-1331.
[PubMed]
https://doi.org/10.1001/jama.297.12.1319
62.
Vazir A, Cowie MR: The use of diuretics in acute heart failure: evidence based therapy? World J Cardiovasc Dis 2013;3:25-34.
https://doi.org/10.4236/wjcd.2013.32A004
63.
Goldsmith SR, Elkayam U, Haught WH, Barve A, He W: Efficacy and safety of the vasopressin V1A/V2-receptor antagonist conivaptan in acute decompensated heart failure: a dose-ranging pilot study. J Card Fail 2008;14:641-647.
[PubMed]
https://doi.org/10.1016/j.cardfail.2008.06.003
64.
Mondritzki T, Kolkhof P, Sabbah HN, Gheorghiade M, Furstner C, Schmeck C, Siedentop H, Schaefer S, Truebel H: Differentiation of arginine vasopressin antagonistic effects by selective V2 versus dual V2/V1a receptor blockade in a preclinical heart failure model. Am J Ther 2010;18:31-37.
[PubMed]
https://doi.org/10.1097/MJT.0b013e3181f890ad
65.
Cuffe MS, Califf RM, Adams KF Jr, Benza R, Bourge R, Colucci WS, Massie BM, O'Connor CM, Pina I, Quigg R, Silver MA, Gheorghiade M: Short-term intravenous milrinone for acute exacerbation of chronic heart failure: a randomized controlled trial. JAMA 2002;287:1541-1547.
[PubMed]
https://doi.org/10.1001/jama.287.12.1541
66.
Abraham WT, Adams KF, Fonarow GC, Costanzo MR, Berkowitz RL, LeJemtel TH, Cheng ML, Wynne J: In-hospital mortality in patients with acute decompensated heart failure requiring intravenous vasoactive medications: an analysis from the Acute Decompensated Heart Failure National Registry (ADHERE). J Am Coll Cardiol 2005;46:57-64.
[PubMed]
https://doi.org/10.1016/j.jacc.2005.03.051
67.
Elkayam U, Tasissa G, Binanay C, Stevenson LW, Gheorghiade M, Warnica JW, Young JB, Rayburn BK, Rogers JG, DeMarco T, Leier CV: Use and impact of inotropes and vasodilator therapy in hospitalized patients with severe heart failure. Am Heart J 2007;153:98-104.
[PubMed]
https://doi.org/10.1016/j.ahj.2006.09.005
68.
Yilmaz MB, Yalta K, Yontar C, Karadas F, Erdem A, Turgut OO, Yilmaz A, Tandogan I: Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther 2007;21:431-435.
[PubMed]
https://doi.org/10.1007/s10557-007-6066-7
69.
Mebazaa A, Nieminen MS, Packer M, Cohen-Solal A, Kleber FX, Pocock SJ, Thakkar R, Padley RJ, Poder P, Kivikko M: Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA 2007;297:1883-1891.
[PubMed]
https://doi.org/10.1001/jama.297.17.1883
70.
Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L: Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trial. Lancet 2002;360:196-202.
[PubMed]
https://doi.org/10.1016/S0140-6736(02)09455-2
71.
Kirkby NS, Hadoke PW, Bagnall AJ, Webb DJ: The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house? Br J Pharmacol 2008;153:1105-1119.
[PubMed]
https://doi.org/10.1038/sj.bjp.0707516
72.
Bax JJ, Casadei B, Di Mario C, Fagard R, Filippatos G, Fox KA, Metra M, Nihoyannopoulos P, Perk J, Rademakers F, Rosenhek R, Vardas PE, Pinto FJ, Ferrari R: Highlights of the 2009 scientific sessions of the European Society of Cardiology. J Am Coll Cardiol 2009;54:2447-2458.
[PubMed]
https://doi.org/10.1016/j.jacc.2009.10.016
73.
Teerlink JR, Iragui VJ, Mohr JP, et al: The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT. Drug Saf 2012;35:233-244.
[PubMed]
https://doi.org/10.2165/11594680-000000000-00000
74.
Gottlieb SS, Givertz MM, Metra M, Gergich K, Bird S, Jones-Burton C, Massie B, Cotter G, Ponikowski P, Weatherley B, O'Connor C, Dittrich H: The effects of adenosine A(1) receptor antagonism in patients with acute decompensated heart failure and worsening renal function: the REACH UP study. J Card Fail 2010;16:714-719.
[PubMed]
https://doi.org/10.1016/j.cardfail.2010.04.006
75.
Cleland JG, Coletta AP, Buga L, Antony R, Pellicori P, Freemantle N, Clark AL: Clinical trials update from the American Heart Association meeting 2010: EMPHASIS-HF, RAFT, TIM-HF, Tele-HF, ASCEND-HF, ROCKET-AF, and PROTECT. Eur J Heart Fail 2011;13:460-465.
[PubMed]
https://doi.org/10.1093/eurjhf/hfr015
76.
Teichman SL, Unemori E, Teerlink JR, Cotter G, Metra M: Relaxin: review of biology and potential role in treating heart failure. Curr Heart Fail Rep 2010;7:75-82.
[PubMed]
https://doi.org/10.1007/s11897-010-0010-z
77.
Du XJ, Bathgate RA, Samuel CS, Dart AM, Summers RJ: Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat Rev Cardiol 2010;7:48-58.
[PubMed]
https://doi.org/10.1038/nrcardio.2009.198
78.
Teerlink JR, Cotter G, Davison BA, et al: Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013;381:29-39.
[PubMed]
https://doi.org/10.1016/S0140-6736(12)61855-8
79.
Mann JF, Schmieder RE, McQueen M, et al: Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial. Lancet 2008;372:547-553.
[PubMed]
https://doi.org/10.1016/S0140-6736(08)61236-2
80.
Parving HH, Brenner BM, McMurray JJ, et al: Cardiorenal end points in a trial of aliskiren for type 2 diabetes. N Engl J Med 2012;367:2204-2213.
[PubMed]
https://doi.org/10.1056/NEJMoa1208799
81.
Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J: The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-717.
[PubMed]
https://doi.org/10.1056/NEJM199909023411001
82.
Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M: Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-1321.
[PubMed]
https://doi.org/10.1056/NEJMoa030207
83.
Eschalier R, McMurray JJ, Swedberg K, van Veldhuisen DJ, Krum H, Pocock SJ, Shi H, Vincent J, Rossignol P, Zannad F, Pitt B: Safety and efficacy of eplerenone in patients at high risk for hyperkalemia and/or worsening renal function: analyses of the EMPHASIS-HF study subgroups (Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure). J Am Coll Cardiol 2013;62:1585-1593.
[PubMed]
https://doi.org/10.1016/j.jacc.2013.04.086
84.
Rossignol P, Dobre D, McMurray JJ, Swedberg K, Krum H, van Veldhuisen DJ, Shi H, Messig M, Vincent J, Girerd N, Bakris G, Pitt B, Zannad F: Incidence, determinants, and prognostic significance of hyperkalemia and worsening renal function in patients with heart failure receiving the mineralocorticoid receptor antagonist eplerenone or placebo in addition to optimal medical therapy: results from the Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure (EMPHASIS-HF). Circ Heart Fail 2014;7:51-58.
[PubMed]
https://doi.org/10.1161/CIRCHEARTFAILURE.113.000792
85.
Zannad F, Gattis Stough W, Rossignol P, et al: Mineralocorticoid receptor antagonists for heart failure with reduced ejection fraction: integrating evidence into clinical practice. Eur Heart J 2012;33:2782-2795.
[PubMed]
https://doi.org/10.1093/eurheartj/ehs257
86.
Swedberg K, Komajda M, Bohm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L: Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010;376:875-885.
[PubMed]
https://doi.org/10.1016/S0140-6736(10)61198-1
87.
Francis GS, Benedict C, Johnstone DE, Kirlin PC, Nicklas J, Liang CS, Kubo SH, Rudin-Toretsky E, Yusuf S: Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the Studies of Left Ventricular Dysfunction (SOLVD). Circulation 1990;82:1724-1729.
[PubMed]
https://doi.org/10.1161/01.CIR.82.5.1724
88.
Isnard R, Pousset F, Trochu J, Chafirovskaia O, Carayon A, Golmard J, Lechat P, Thomas D, Bouhour J, Komajda M: Prognostic value of neurohormonal activation and cardiopulmonary exercise testing in patients with chronic heart failure. Am J Cardiol 2000;86:417-421.
[PubMed]
https://doi.org/10.1016/S0002-9149(00)00957-7
89.
Gheorghiade M, Rossi JS, Cotts W, Shin DD, Hellkamp AS, Pina IL, Fonarow GC, DeMarco T, Pauly DF, Rogers J, DiSalvo TG, Butler J, Hare JM, Francis GS, Stough WG, O'Connor CM: Characterization and prognostic value of persistent hyponatremia in patients with severe heart failure in the ESCAPE Trial. Arch Intern Med 2007;167:1998-2005.
[PubMed]
https://doi.org/10.1001/archinte.167.18.1998
90.
Udelson JE, McGrew FA, Flores E, Ibrahim H, Katz S, Koshkarian G, O'Brien T, Kronenberg MW, Zimmer C, Orlandi C, Konstam MA: Multicenter, randomized, double-blind, placebo-controlled study on the effect of oral tolvaptan on left ventricular dilation and function in patients with heart failure and systolic dysfunction. J Am Coll Cardiol 2007;49:2151-2159.
[PubMed]
https://doi.org/10.1016/j.jacc.2007.01.091
91.
Komajda M, Anker SD, Charlesworth A, Okonko D, Metra M, Di Lenarda A, Remme W, Moullet C, Swedberg K, Cleland JG, Poole-Wilson PA: The impact of new onset anaemia on morbidity and mortality in chronic heart failure: results from COMET. Eur Heart J 2006;27:1440-1446.
[PubMed]
https://doi.org/10.1093/eurheartj/ehl012
92.
van Deursen VM, Urso R, Laroche C, Damman K, Dahlstrom U, Tavazzi L, Maggioni AP, Voors AA: Co-morbidities in patients with heart failure: an analysis of the European Heart Failure Pilot Survey. Eur J Heart Fail 2014;16:103-111.
[PubMed]
https://doi.org/10.1002/ejhf.30
93.
Komajda M: Prevalence of anemia in patients with chronic heart failure and their clinical characteristics. J Card Fail 2004;10:S1-S4.
[PubMed]
https://doi.org/10.1016/j.cardfail.2004.01.003
94.
Silverberg DS, Wexler D, Blum M, Keren G, Sheps D, Leibovitch E, Brosh D, Laniado S, Schwartz D, Yachnin T, Shapira I, Gavish D, Baruch R, Koifman B, Kaplan C, Steinbruch S, Iaina A: The use of subcutaneous erythropoietin and intravenous iron for the treatment of the anemia of severe, resistant congestive heart failure improves cardiac and renal function and functional cardiac class, and markedly reduces hospitalizations. J Am Coll Cardiol 2000;35:1737-1744.
[PubMed]
https://doi.org/10.1016/S0735-1097(00)00613-6
95.
Ngo K, Kotecha D, Walters JA, Manzano L, Palazzuoli A, van Veldhuisen DJ, Flather M: Erythropoiesis-stimulating agents for anaemia in chronic heart failure patients. Cochrane Database Syst Rev 2010;1:CD007613.
[PubMed]
https://doi.org/10.1002/14651858.CD007613.pub2
96.
Swedberg K, Young JB, Anand IS, Cheng S, Desai AS, Diaz R, Maggioni AP, McMurray JJ, O'Connor C, Pfeffer MA, Solomon SD, Sun Y, Tendera M, van Veldhuisen DJ: Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013;368:1210-1219.
[PubMed]
https://doi.org/10.1056/NEJMoa1214865
97.
Anker SD, Comin Colet J, Filippatos G, Willenheimer R, Dickstein K, Drexler H, Luscher TF, Bart B, Banasiak W, Niegowska J, Kirwan BA, Mori C, von Eisenhart Rothe B, Pocock SJ, Poole-Wilson PA, Ponikowski P: Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009;361:2436-2448.
[PubMed]
https://doi.org/10.1056/NEJMoa0908355
98.
Beck-da-Silva L, Piardi D, Soder S, Rohde LE, Pereira-Barretto AC, de Albuquerque D, Bocchi E, Vilas-Boas F, Moura LZ, Montera MW, Rassi S, Clausell N: IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia. Int J Cardiol 2013;168:3439-3442.
[PubMed]
https://doi.org/10.1016/j.ijcard.2013.04.181
99.
Weinberg ED: Iron loading and disease surveillance. Emerg Infect Dis 1999;5:346-352.
[PubMed]
https://doi.org/10.3201/eid0503.990305
100.
Sullivan JL: Long-term risks of increased use of intravenous iron. Lancet 2007;370:481-482, author reply 482-483.
[PubMed]
https://doi.org/10.1016/S0140-6736(07)61225-2
101.
Dickstein K, Vardas PE, Auricchio A, Daubert JC, Linde C, McMurray J, Ponikowski P, Priori SG, Sutton R, van Veldhuisen DJ: 2010 Focused Update of ESC Guidelines on device therapy in heart failure: an update of the 2008 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-2687.
[PubMed]
https://doi.org/10.1093/eurheartj/ehq337
102.
Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang AS: An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J 2013;34:3547-3556.
[PubMed]
https://doi.org/10.1093/eurheartj/eht290
103.
Teerlink JR, Clarke CP, Saikali KG, Lee JH, Chen MM, Escandon RD, Elliott L, Bee R, Habibzadeh MR, Goldman JH, Schiller NB, Malik FI, Wolff AA: Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study. Lancet 2011;378:667-675.
[PubMed]
https://doi.org/10.1016/S0140-6736(11)61219-1
104.
Mitrovic V, Seferovic PM, Simeunovic D, Ristic AD, Miric M, Moiseyev VS, Kobalava Z, Nitsche K, Forssmann WG, Luss H, Meyer M: Haemodynamic and clinical effects of ularitide in decompensated heart failure. Eur Heart J 2006;27:2823-2832.
[PubMed]
https://doi.org/10.1093/eurheartj/ehl337
105.
Fonarow GC: Comparative effectiveness of diuretic regimens. N Engl J Med 2011;364:877-878.
[PubMed]
https://doi.org/10.1056/NEJMe1014162
© 2014 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2014
You do not currently have access to this content.